Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Urinary Bladder Neoplasms 1Neoplasm, Residual 1Lymphoma, Large B-Cell, Diffuse 1Carcinoma, Transitional Cell 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 16Vincristine 12Prednisone 11Methotrexate 11Etoposide 9Cytarabine 9merphos 8blinatumomab 8venetoclax 7prednylidene 7pegaspargase 7deltacortene 7Specimen Handling 7Mercaptopurine 7Dexamethasone 7azathiopurine 6N,N-dicyclohexyl-isoborneol-10-sulfonamide 6Doxorubicin 6Calcium Dobesilate 6dexamethasone acetate 5dexamethasone 21-phosphate 5auricularum 5Spinal Puncture 5Rituximab 5Leucovorin 5Biopsy 5fludarabine phosphate 4Stem Cell Transplantation 4Methylprednisolone 4Inotuzumab Ozogamicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Burkitt Lymphoma × NKTR-255 × Clear all
NCT03233854 2025-11-18

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

Stanford University

Phase 1 Active not recruiting
56 enrolled
Lymphoid

Burkitt Lymphoma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡